3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA

February 26, 2015

In this poster presentation, Dr. Chris Parker presented updated safety data from the ALSYMPCA trial. The ALSYMPCA trial was a phase III randomized, double-blind, placebo-controlled trial published in 2013 which demonstrated an overall survival benefit and increased time to a first skeletal-related event with the administration of radium-223 to men with metastatic CRPC with multiple symptomatic bony metastases.

At the time of initial publication and subsequent follow-up studies, radium-223 was found to have a favorable safety profile, owing to decreased depth of penetration of alpha particles, and thus decreased risk for myelosuppression. In this study presenting 3-year safety data, the authors reported that in both the radium-223 and placebo groups, over 90% of patients reported experiencing at least one treatment-related adverse event in the initial treatment period including the time up to 12 weeks from the last injection.

Read the full story.